Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.60 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969971 | 0.93 | MME (0.70) | MMEACESCN9AMMEL1CTSS | |
| SCHEMBL20099589 | 0.93 | MME (0.70) | MMEACESCN9AMMEL1CTSS | |
| SCHEMBL11973757 | 0.93 | MME (0.70) | MMEACESCN9AMMEL1CTSS | |
| SCHEMBL18874742 | 0.90 | MME (0.53) | MMEACESCN9AMMEL1CTSS | |
| SCHEMBL18874681 | 0.90 | MMEL1 (0.49) | MMEACESCN9AMMEL1 | |
| SCHEMBL19222886 | 0.86 | MME (0.60) | MMEACESCN9AMMEL1CTSS | |
| SCHEMBL18386377 | 0.86 | MME (0.46) | MMESCN9ACTSSCTSKMMP2 | |
| SCHEMBL11969628 | 0.84 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL18626426 | 0.83 | MME (0.59) | MME | |
| SCHEMBL12975711 | 0.83 | MME (0.52) | MMEACESCN9AMMEL1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885ACE 4/4885SCN9A 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.